Cognitive impairment associated with increased mortality rate in patients with heart failure: A systematic review and meta-analysis

Jakrin Kewcharoen a,b,⇑, Narut Prasitlumkum a, Chanavuth Kanitsoraphan a, Nattawat Charoenpoonsiri b, Natthapon Angsubhakorn c, Prapaipan Putthapiban d, Pattara Rattanawong a,e

a University of Hawaii Internal Medicine Residency Program, Honolulu, HI
b Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok
c University of Minnesota Medical School, Department of Medicine, Minneapolis, MN
d Department of Medicine, Einstein Medical Center, Philadelphia, PA
e Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok

a,c,d USA
b,e Thailand

Background: Recent systematic review and meta-analysis showed that the prevalence of cognitive impairment was significantly increased in patients with heart failure (HF) when compared to the general population. However, the effect of cognitive impairment on cardiovascular outcome in this population is still unclear. We performed a systematic review and meta-analysis to assess whether cognitive impairment associated with worse outcome in patients with HF.

Methods: We comprehensively searched the databases of MEDLINE and EMBASE from inception to October 2018. Included studies were published cohort (prospective or retrospective) or randomized control trials that evaluate the effect of cognitive impairment mortality in HF patients. Data from each study were combined using the random-effects, generic inverse variance method of DerSimonian and Laird to calculate pooled hazard ratios (HR) and 95% confidence intervals (CI).

Results: Eight studies were included in the analysis involving 3318 participants (951 participants had cognitive impairment). In a random-effects model, our analysis demonstrated that cognitive impairment significantly increased the risk of mortality in HF patients (pooled HR = 1.64, 95% CI = 1.42–1.88, I² = 0.0%, p < 0.001).

Conclusion: Our systematic review and meta-analysis showed that the presence of cognitive impairment is strongly associated with an increased mortality risk in the HF population. Further research is needed to explore the pathophysiology of this association.

© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Cognitive dysfunction, Heart failure, Mortality

Disclosure: Authors have nothing to disclose with regard to commercial support.

Received 11 January 2019; revised 25 May 2019; accepted 8 June 2019.
Available online 18 June 2019

⇑ Corresponding author at: 1212 Nuuanu ave, Honolulu, HI 96817, USA.
E-mail address: jakrin@hawaii.edu (J. Kewcharoen).
1. Introduction

Heart failure (HF) is a very common cardiovascular disease and one of the leading causes of hospitalization and mortality worldwide, especially in older adults [1,2]. The mortality rate from HF has been decreasing significantly in past few decades due to the implementation of beta-blockers, renin-angiotensin-aldosterone system blockers, coronary revascularization, implantable cardioverter-defibrillator, and cardiac resynchronization therapies [3]. However, the mortality rate remained high with 5-year mortality up to 42.3% in patients hospitalized for HF [4]. Identifying clinical prognosticating factors in such patients is among foci of clinical research. Several factors have been found associated with a worse cardiovascular outcome and an increased mortality in patients with HF. These factors include, but not limited to, increased resting heart rate, low ejection fraction, raised creatinine, New York Heart Association Class III/IV, history of left bundle branch block, low systolic blood pressure, and older age [5].

Cognitive dysfunction is a common condition in patients with HF. A systematic review including 4176 participants in 26 cohorts revealed the prevalence of cognitive impairment at 43% in patients with HF [6]. Among such patients, cognitive dysfunction has been found associated with poorer medical adherence [7], lower ability for self-care [8], lower disease awareness [9], increased hospitalization [10], and higher cardiovascular events [11].

Several studies have been conducted to study the impact of cognitive impairment on mortality in patients with HF [12–18]. However, there has been no systematic review or meta-analysis to confirm this relation. This is the first meta-analysis to evaluate the association between cognitive impairment and long-term mortality in patients with HF.

2. Methods

2.1. Search strategy

Two investigators (NP and CK) independently searched for published studies indexed in MEDLINE and EMBASE databases from inception to October 2018 using a search strategy that included the terms “cognitive impairment”, “cognitive dysfunction”, “heart failure”, and “mortality”. Publications in only English language were included. A manual search for additional pertinent studies and review articles using references from retrieved articles was also completed.

2.2. Inclusion criteria

The eligibility criteria included the following:

(1) Cohort studies (prospective or retrospective) or randomized controlled trials of HF patients with and without cognitive impairment that compared all-cause mortality rate between the two populations.

(2) Relative risk, hazard ratio (HR), odds ratio, incidence ratio, or standardized incidence ratio with 95% confidence intervals (CIs) or sufficient raw data for these calculations had to be provided.

Study eligibility was independently determined by two investigators (NP and CK) and differences were resolved by mutual consensus. Newcastle–Ottawa quality assessment scale, ranging from 0 to 9, was used to evaluate each cohort study in three domains: recruitment and selection of the participants, similarity and comparability between the groups, and ascertainment of the outcome of interest among cohort studies [19]. Cochrane Collaboration tool for assessing risk of bias was used to evaluate the quality of each randomized controlled trial [20].

2.3. Data extraction

A standardized data collection form was used to obtain the following information from each study: name of first author, year of the study, country of origin, study type, inclusion and exclusion criteria, number and demographic data of the participants, duration of follow-up, diagnostic method of HF, mortality rate, assessment tools used to identify cognitive impairment, adjusted confounders and conclusion by authors.

To ensure accuracy, two investigators (NP and CK) independently performed this data extraction process. Should there be any data discrepancy, we referred back to the original articles.

2.4. Definition

HF was diagnosed differently as defined in each study (Table 1). Cognitive impairment was defined as an abnormality of at least one of the five domains of the cognitive function [21] or as

| Abbreviations |
|---------------|
| CI            | Confidence Interval |
| HF            | Heart Failure       |
| HR            | Hazard ratio        |
| First author | Year | Country | Study type | Inclusion criteria | Exclusion criteria | Mean age (SD) | Male (%) | Follow-up (months) | Total participants (n) | HF diagnostic method | Mortality rate (%) | CI screening method and diagnosis | Patients with CI (%) | Confounder adjustment | Conclusion |
|--------------|------|---------|------------|-------------------|-------------------|---------------|-----------|-----------------|---------------------|---------------------|----------------|--------------------------------|------------------|---------------------|-------------|
| Gonz         | 2014 | Spain   | Randomized controlled trial | Individuals diagnosed with acute HF and discharged from Geriatric Service of the Caceres Hospital complex | N/A | 85 (N/A) | 27 | 12 | 116 | According to the European Society of Cardiology Guidelines 2008 | 30.1 | GDS ≥3 | 19.8 | N/A | Participants without CI in disease management program had lower probability of CV event. This effect was not seen in the CI group. |
| Huijts       | 2013 | Netherlands | Retrospective cohort | HF patients age ≤40 years old with HF, history of HF hospitalization within the past year, NT-proBNP higher than twice the upper limit of normal | Dyspnea not mainly from HF, valvular heart disease, short life expectancy, recent angina, history of revascularization | 76 (8) | 61.3 | 18 | 382 | Signs and symptoms of HF or currently NYHA class ≥2 and on HF therapy | N/A | AMT ≤7 | 9.2 | N/A | CI is often unrecognized in HF patients, but the influence of HF severity and its changes on cognitive function were less than hypothesized. CI was an independent risk factor for mortality in patients with HF. |
| Lan          | 2018 | USA     | Retrospective cohort | Outpatient veterans with a clinical diagnosis of HF without previous history of CI | Life expectancy of less than 6 months or documented dementia requiring a caregiver | 66.4 (N/A) | 98.8 | 36 | 250 | | N/A | 25.6 | SLUMS <25 | 57.6 | Demographics data, comorbidity, LVEF, SLUMS score | CI was an independent risk factor for mortality in patients with HF. |
| McLennan     | 2006 | Australia | Randomized controlled trial | HF patients with EF ≤55% and NYHA ≥2 | HF patients with EF ≤55% and NYHA ≥2 | 75.6 (8) | 60.1 | 60 | 200 | Diagnosed by confirmed LVEF <55% and NYHA ≥2 | 96.3 | MMSE ≤26 | 13.5 | N/A | CI was an independent risk factor for mortality in CHF. |
| Murad        | 2015 | USA     | Prospective cohort | Participants from the Cardiovascular Health Study who developed HF | N/A | 79.2 (6.3) | 51.8 | 120 | 558 | Clinical diagnosis made by a treating physician, and being on medications for HF including both a diuretic and either a digitalis preparation or a vasodilator | 83 | 3MSE <80 | 17.4 | Demographic data, functional impairment | Some of comorbidities in elderly with incident HF are associated with greater mortality risk. |
| Study            | Year | Country | Study Design       | Inclusion Criteria                                                                 | Exclusion Criteria                                                                 | Cohort Characteristics | Diagnosis Determination                                                                 | MMSE CI | Demographic Data, Comorbidity | Psychological Factors |
|------------------|------|---------|--------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------|------------------------------------------------------------------------------------------|---------|-----------------------------|----------------------|
| Del Sindaco 2012 | Italy| Retrospective cohort | HF patients >70 years old with NYHA ≥3 Valvular heart disease, active substance abuse, psychiatric illness, dementia, short life expectancy, non-consent patient, living in nursing care |   | Diagnosis was determined according to the European Society of Cardiology Guidelines 2001 | 77 (4.6)               | 52.0 24 173                                                                            | 31.4 | MMSE ≤24                     | CI is very common and associated with worse prognosis in HF patients |
| Sokoreli 2018 UK | Prospective observational study | HF patients >18 years old, live in the region served by the Hull and East Yorkshire hospitals NHS trust and hospitalized for HF and on treatment with loop diuretics Unable to understand and comply with the protocol. Unable or unwilling to give informed consent. |   | At least one of the following: LVEF ≤40%, left atrial dimension >4.0 cm, 8 or NT-proBNP >400/1200 pg/ml for sinus rhythm/atrial fibrillation | 76 (15)               | 66 12 671                                                                             | 15.6 | GPCOG ≤4                     | Psychological factors are strongly associated with unplanned recurrent readmissions or mortality following an admission for HF |
| Zucala 2003 Italy | Retrospective cohort | Patients admitted with principal diagnosis of HF None |   | Clinically diagnosed by the study researchers | 78 (9)               | 53.9 12 968                                                                            | 16   | AMT <7                      | CI is an independent prognostic marker in older patients with HF |

3MSE = modified mini-mental state exam; AMT = Hodkinson abbreviated mental test; CI = cognitive impairment; CV = cardiovascular; GDS = global deterioration scale; GPCOG = general practitioner assessment of cognition; HADS = hospital anxiety and depression scale; HF = heart failure; LVEF = left ventricular ejection fraction; MMSE = mini-mental state examination; N/A = not available; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart American Classification; SLUMS = The Saint Louis University Mental Status.
defined in each study (Table 1). Mortality was defined by all-cause mortality during the follow-up period.

2.5. Statistical analysis

The meta-analysis was performed using a random-effects model. The extracted studies were excluded from the analysis if they did not justify an outcome in each cohort. We pooled the point estimates from each study using the generic inverse-variance method of Der Simonian and Laird [22]. The heterogeneity of effect size estimates across these studies was measured using the $I^2$ statistic. The $I^2$ statistic ranges in value from 0% to 100% ($I^2 < 25\%$, low heterogeneity; $I^2 = 25–50\%$, moderate heterogeneity; $I^2 > 50\%$, substantial heterogeneity). A sensitivity analysis was also conducted. Publication bias was assessed using a funnel plot and Egger’s regression test ($p < 0.05$ was considered significant). All data analyses were performed using the StataCorp 2015, Stata: Release 14, Statistical Software (StataCorp LP, College Station, TX).

3. Results

3.1. Study inclusion and characteristic

In total, 303 potentially relevant studies (full articles) conducted were identified (88 studies from EMBASE, 215 studies from PUBMED). After exclusion of 72 duplicate studies, 231 studies underwent title and abstract review. After the

Figure 1. PRISMA flow diagram demonstrating search strategy and selection process.
initial reviewed, 198 studies were excluded as they were not conducted in HF patients with cognitive impairment, and 33 studies underwent full-article review. A further 25 studies were excluded as they did not have a control group and/or did not report all-cause mortality rate and/or did not have a clear definition of cognitive impairment. Therefore, eight eligible studies with a total of 3318 participants (951 participants had cognitive impairment) were included for meta-analysis. The PRISMA diagram flow is demonstrated in Fig. 1. Mortality rate was compared between HF patients with and without cognitive impairment. The prevalence of cognitive impairment ranged from 9.2% to 57.6% across the included studies. Characteristics of the included studies in the meta-analysis are summarized in Table 1.

3.2. Quality of eligible studies

The quality of the included cohort studies and randomized controlled trials were evaluated by the Newcastle–Ottawa Scale and the Cochrane Collaboration tool for assessing risk of bias, respectively (Supplementary file 2 and 3).

3.3. Quantitative analyses

In random-effect model, our analysis showed that the presence of cognitive impairment significantly increased the risk of mortality in HF patients with pooled HR of 1.64 (95% CIs: 1.42, 1.88, $I^2 = 0.0\%$, $p < 0.001$; Fig. 2).

3.4. Sensitivity analysis

We assessed the stability of the meta-analysis results. We conducted a sensitivity analysis by excluding one study at a time. None of the results were significantly altered, as the results after removing one study at a time were consistent with the main meta-analysis. This indicated that our results were robust.

3.5. Publication bias

Funnel plot and Egger’s test were performed to confirm absent of publication bias. The funnel plot (Fig. 3) was symmetric indicating no publication bias.

---

**Table 1:** Characteristics of the included studies in the meta-analysis

| First author, year | HR (95%CI) | Weight |
|--------------------|------------|--------|
| Gonz, 2015         | 1.85 (1.07, 3.21) | 6.50 |
| Huijts, 2013       | 1.53 (1.02, 2.30) | 11.84 |
| Lan, 2018          | 1.82 (1.04, 3.20) | 6.15 |
| McLennan, 2006     | 2.19 (1.41, 3.40) | 10.18 |
| Murad, 2015        | 1.33 (1.02, 1.73) | 28.06 |
| Sindaco, 2012      | 2.08 (1.10, 3.93) | 4.81 |
| Sokoreli           | 1.43 (0.90, 2.28) | 9.06 |
| Zuccala, 2003      | 1.80 (1.35, 2.41) | 23.40 |

Overall (I-squared = 0.0%, $p = 0.564$)

Heterogeneity chi-squared = 5.80 (d.f. = 7) $p = 0.564$

$z = 6.90 p < 0.001$

NOTE: Weights are from random effects analysis.
bias, and Egger’s test reported no small studies effect (95% CI: –0.91, 3.93, \( p = 0.179 \); Fig. 4).

4. Discussion

To the best of our knowledge, this is the first meta-analysis examining the association between cognitive impairment and mortality in the HF population. Our meta-analysis showed a 1.64-fold increase in mortality rate among HF patients with cognitive impairment compared with that among those without cognitive impairment.

Huijts et al. [13] reported the lowest cognitive impairment prevalence at 9.2%, whereas the study by Lan et al. [14] showed the highest cognitive impairment prevalence at 57.6%. This major difference was likely due to a variation in participants’ demographic and screening instruments. Every included study reported a significant association between the presence of cognitive impairment and an increased mortality rate in HF patients. Despite the highest reported cognitive impairment prevalence in the study by Lan et al. [14], the highest mortality rate was found in the study by McLennan et al. [15] (96.3%), which followed patients up to 60 months. The study by Murad et al. [17] had the longest follow-up duration (120 months) and reported the relatively high mortality rate of 83%. The study by Zuccala et al. [18], which had the highest number of participants (\( n = 968 \)), reported the cognitive impairment prevalence and mortality rate at 24.6% and 16%, respectively.

Although the differences in study characteristics were obvious, the low level of heterogeneity among studies is particularly interesting suggesting that the effect of cognitive impairment on mortality is consistent despite the variation in demographics, screening tools, and follow-up duration. As there is still not enough evidence regarding the most sensitive and specific method and the optimal timing for cognitive screening in HF population [23], this could imply that different instrument may be equally effective in screening for cognitive impairment, and the diverse cognitive impairment prevalence was mainly from the difference in participants’ demographics. Moreover, the effect of cognitive impairment on mortality could be similar on both short- and long-term follow-up. Nevertheless, this further strengthens the result of our meta-analysis and confirms the existence of this relation.

Recent evidence from a systematic review and meta-analysis found a significant association between cognitive impairment and HF [6]. Several mechanisms have been suggested to explain this finding. One is the low systolic blood pressure found to be associated with the presence of cognitive impairment in the HF population [24]. In addition to cardioembolic emboli and other comorbidities, this leads to chronic poor cerebral perfusion and progressive degeneration of the brain [25]. Some factors, such as anemia, chronic kidney disease, older age, and lower left ventricular ejection fraction, were also found relating to the presence of cognitive impairment in HF patients [26–28]. Despite the recommendation to screen for cognitive impairment in HF patients, the dysfunction of cognition in the majority of HF patients was still undetected [29]. One study revealed that by the time of discharge, as little as 23% of HF patients with impaired cognition had it documented [30].

Management of cognitive impairment in HF is still in debate. Patients with cognitive impairment were found to have less effective self-care and medical non-compliance [31–33]. However, there is no data showing that improving HF knowledge or lifestyle could reduce cardiovascular outcome in the HF population with cognitive impairment. Currently, delaying the progression of cognitive impairment by targeting comorbidities, such as hypertension, atrial fibrillation and depression seem to be beneficial [34]. More research is needed to explore an effective intervention in reducing cardiovascular outcome in HF patients with cognitive impairment.

4.1. Strengths and limitations

The strength of this meta-analysis is that most studies were prospective studies. The result from our analysis showed heterogeneity of 0.0%, which demonstrated the consistency of the results among the included studies.

We also found limitations. First, the included studies did not report the type or classification of
the HF. Secondly, HRs from the study by Gonz et al. [35], Huijts et al. [13], and Zuccala et al. [18] were not adjusted for other variables, and outcome from the study by Sokoleri et al. [36] also included re-hospitalization rate. However, subgroup analysis without the four studies still showed a significant association between cognitive impairment and mortality in HF patients (Fig. 5). Lastly, each study used different cognitive screening tools and had various follow-up durations. Nevertheless, the absence of heterogeneity implied that each study reported comparable HR and could be combined for meta-analysis.

5. Conclusions

In conclusion, our systematic review and meta-analysis showed that the presence of cognitive impairment is strongly associated with an increased mortality rate among patients with HF. This emphasizes the necessity for cognitive assessment among HF population. Further research is needed to explore the pathophysiology and to appropriately manage the dysfunction of cognition in this population.

Funding details

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors report no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jsha.2019.06.001.

References

[1] van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016;18:242–52.
[2] Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 2015;131:e29–e322.
[3] Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail 2014;16:317–24.
[4] Chang PP, Chambless LE, Shahar E, Bertoni AG, Russell SD, Ni H, et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2014;113:504–10.
[5] Ford I, Robertson M, Komajda M, Böhm M, Borer JS, Tavazzi L, et al. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT Risk Model. Int J Cardiol 2015;184:163–9.
[6] Cannon JA, Moffitt P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJ, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail 2017;23:464–75.
[7] Mixon AS, Myers AP, Leak CL, Jacobsen JM, Cawthon C, Goggins KM, et al. Characteristics associated with postdischarge medication errors. Mayo Clin Proc 2014;89:1042–51.
[8] Harkness K, Heckman GA, Akhtar-Danesh N, Demers C, Gunn E, McKelvie RS. Cognitive function and self-care management in older patients with heart failure. Eur J Cardiovasc Nurs 2014;13:277–84.
[9] Dennison CR, McIntee ML, Samuel L, Johnson BJ, Rotman S, Kiely A, et al. Adequate health literacy is
associated with higher heart failure knowledge and self-care confidence in hospitalized patients. J Cardiovasc Nurs 2011;26:359–67.

[10] Wu JR, Holmes GM, DeWalt DA, Macabasco-O’Connell A, Bibbens-Domingo K, Ruo B, et al. Low literacy is associated with increased risk of hospitalization and death among individuals with heart failure. J Gen Intern Med 2013;28:1174–80.

[11] Gelow JM, Mudd JO, Chien CV, Lee CS. Usefulness of cognitive dysfunction in heart failure to predict cardiovascular risk at 180 days. Am J Cardiol 2015;115:778–82.

[12] Del Sindaco D, Pulignano G, Di Lenarda A, Tarantini L, Cioffi G, Tolone S, et al. Role of a multidisciplinary program in improving outcomes in cognitively impaired heart failure older patients. Monaldi Arch Chest Dis 2012;78:20–8.

[13] Huijts M, van Oostenbrugge RJ, Duits A, Burkard T, Muzzarelli S, Maeder MT, et al. Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial. Eur J Heart Fail 2013;15:699–707.

[14] Lan H, Hawkins LA, Kashmer M, Perez E, Firek CJ, Silvet H. Cognitive impairment predicts mortality in outpatient veterans with heart failure. Heart Lung 2018;47:546–52.

[15] McLennan SN, Pearson SA, Cameron J, Stewart S. Prognostic importance of cognitive impairment in chronic heart failure patients: does specialist management make a difference? Eur J Heart Fail 2006;8:494–501.

[16] O’Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, et al. Cognitive impairment and risk of cardiovascular events and mortality. Eur Heart J 2012;33:1777–86.

[17] Murad K, Goff Jr DC, Morgan TM, Burke GL, Bartz TM, Kizer JR, et al. Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study. JACC Heart Fail 2015;3:542–50.

[18] Zuccala G, Pedone C, Cesari M, Onder G, Pahor M, Marzetti E, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 2003;115:97–103.

[19] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[20] Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[21] Knoaman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. Mayo Clin Proc 2014;89:1452–9.

[22] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.

[23] Cameron J, Gallagher R, Pressler SJ. Detecting and managing cognitive impairment to improve engagement in heart failure self-care. Curr Heart Fail Rep 2017;14:13–22.

[24] Zuccala G, Onder G, Pedone C, Carosella L, Pahor M, Bernabei R, et al. Hypotension and cognitive impairment: Selective association in patients with heart failure. Neurology 2001;57:1986–92.

[25] Georgiadis D, Sievert M, Cencetti S, Uhmann F, Krivokuca M, Zierer S, et al. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000;21:407–13.

[26] Pulignano G, Del Sindaco D, Di Lenarda A, Tinti MD, Tarantini L, Cioffi G, et al. Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. J Cardiovasc Med 2014;15:481–90.

[27] Jurgens CY, Faulkner KM, Lee CS. Phentypic profiling of cognitive impairment risk among patients with heart failure: a literature review of the usefulness of cardiac-related variables. Eur J Cardiovasc Nurs 2013;12:109–31.

[28] Dardiotis E, Giamouzis G, Mastrogianiss D, Vogiatzi C, Skoularigis J, Triposkiadis F, et al. Cognitive impairment in heart failure. Cardiol Res Pract 2012;2012:595821.

[29] Moyer VA. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:791–7.

[30] Dodson JA, Truong TT, Towle VR, Kerins G, Chaudhry SI. Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. Am J Med 2013;126:120–6.

[31] Curie K, Rideout A, Lindsay G, Harkness K. The association between mild cognitive impairment and self-care in adults with chronic heart failure: a systematic review and narrative synthesis. J Cardiovasc Nurs 2015;30:382–96.

[32] Hawkins LA, Kilian S, Firek A, Kashmer TM, Firek CJ, Silvet H. Cognitive impairment and medication adherence in outpatients with heart failure. J Crit Care 2012;41:572–82.

[33] Davis KK, Mintzer M, Dennison Himmellabar CR, Hayat MJ, Rotman S, Allen J. Targeted intervention improves knowledge but not self-care or readmissions in heart failure patients with mild cognitive impairment. Eur J Heart Fail 2012;14:1041–9.

[34] Yzeiraj E, Tam DM, Gorodeski EZ. Management of cognitive impairment in heart failure. Curr Treat Options Cardiovasc Med 2016;18:4.

[35] Gonzalez-Guerrero JI, Alonso-Fernandez T, Garcia-Mayolín N, Gusi N, Ribera-Casado JM. Effect of A Follow-Up Program in Elderly Adults with Heart Failure with Cognitive Impairment After Hospital Discharge. Journal of the American Geriatrics Society. 2015;63 (9):1950–1.

[36] Sokoreli I, Pauws SC, Steyerberg EW, de Vries GJ, Riistama JM, Tesanovic A, Kazmi S, Pellicori P, Cleland JG, Clark AL. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study. Eur J Heart Fail. 2018;20(4):689–96.